Results 1 to 10 of about 17,271 (194)

Abiraterone-Induced Endocrinopathies [PDF]

open access: yesJCEM Case Reports, 2023
Abstract Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. However, little is documented in the endocrinology literature about the incidences of the endocrine side effects of abiraterone.
Scarlett Decamps   +2 more
openaire   +5 more sources

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

open access: yesIJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani   +7 more
doaj   +2 more sources

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

open access: yesCase Reports in Urology, 2018
Introduction. The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to ...
Yutaka Yamamoto   +7 more
doaj   +2 more sources

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

open access: yesFrontiers in Oncology, 2022
BackgroundAbiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently demonstrated in other outcome studies from real-world ...
Pei-Yu Li   +6 more
doaj   +1 more source

Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol® Enabled Amorphous Solid Dispersions

open access: yesPharmaceutics, 2020
Abiraterone is a poorly water-soluble drug. It has a high melting point and limited solubility in organic solvents, making it difficult to formulate as an amorphous solid dispersion (ASD) with conventional technologies.
Urvi Gala   +2 more
doaj   +1 more source

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Oncology, 2021
ObjectiveThe androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC).
ZhenHeng Wei   +4 more
doaj   +1 more source

Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets

open access: yesJCO Global Oncology, 2020
PURPOSEIt is projected that approximately 50,000 new cases of prostate cancer will be diagnosed in 2020 in India. Survival has improved because of the development of effective drugs such as abiraterone acetate, but universal accessibility to treatment is
Amol Patel   +11 more
doaj   +1 more source

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

open access: yesFrontiers in Oncology, 2021
BackgroundBoth abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of ...
Rachel Raju   +6 more
doaj   +1 more source

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation

open access: yesFrontiers in Oncology, 2021
Abiraterone acetate and Enzalutamide are novel anti-androgens that are key treatments to improve both progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.
Timothy C. Wright   +8 more
doaj   +1 more source

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy

open access: yesTherapeutic Advances in Urology, 2015
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone ...
Benjamin A. Gartrell, Fred Saad
doaj   +1 more source

Home - About - Disclaimer - Privacy